Ratings Moves: AIR,...
Health Care: Drugs
AstraZeneca PLC (AZN: NYSE)
$51.56 -0.27 | -0.52%
05/17/13 - 04:00 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | 0.00 | 0.00 | 10.98B | 0.00 |
| Operating Gains/Losses | 0.00 | 428.00M | 0.00 | 0.00 |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 755.00M | -1.11B | 10.00M | -256.00M |
| (Increase) Decrease in Inventories | -150.00M | -256.00M | 88.00M | 6.00M |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | -1.31B | 467.00M | -16.00M | 1.58B |
| (Decrease) Increase In Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Working Capital | 0.00 | 0.00 | 0.00 | -200.00M |
| Other Non-Cash Items | 5.14B | 5.74B | -3.12B | 8.52B |
| Net Cash From Continuing Operations | 6.95B | 7.82B | 10.68B | 11.74B |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | 6.95B | 7.82B | 10.68B | 11.74B |
| Sale of Property, Plant & Equipment | 199.00M | 102.00M | 293.00M | 407.00M |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Property, Plant & Equipment | -4.62B | -1.30B | -2.18B | -2.96B |
| Acquisitions | -1.19B | 1.77B | -348.00M | 0.00 |
| Purchases of Short-Term Investments | 0.00 | 0.00 | -239.00M | 0.00 |
| Other Cash from Investing Activities | 3.75B | -2.59B | 164.00M | 102.00M |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -1.86B | -2.02B | -2.34B | -2.48B |
| Issuance of Debt | 1.98B | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 429.00M | 409.00M | 494.00M | 135.00M |
| Repayment of Long-Term Debt | -1.77B | 46.00M | -1.75B | -787.00M |
| Repurchase of Capital Stock | -2.64B | -6.02B | -2.60B | 0.00 |
| Payment of Cash Dividends | -3.66B | -3.76B | -3.36B | -2.98B |
| Other Financing Charges, Net | 735.00M | 3.00M | 0.00 | 0.00 |
| Net Cash From Financing Activities | -4.92B | -9.32B | -7.22B | -3.63B |
| Effect of Exchange Rate Changes | -4.00M | -25.00M | 33.00M | 71.00M |
| Net Change in Cash & Cash Equivalents | 162.00M | -3.55B | 1.15B | 5.70B |
Portfolios with AZN
- Portfolio NameUser Type
- UserDC
- ContributorRocket Stocks for the Week ...
- ContributorRocket Stocks for the Week ...
- Contributor7 Big-Pharma Stocks With Un...
- UserCurrent
- Contributor9 High-Yield Stocks to Cons...
- UserGFNN Stockdiagnostics 14
- UserThe Coming M&A boom
- ContributorHighest-Yielding Drug Stocks
- Contributor10 Dividend Stocks Still Pa...
Latest AZN Headlines from TheStreet
- 5 Stocks Dragging In The Health Care Sector 05.06.13 | 01:05 pm
- 4 Buy-Rated Dividend Stocks 05.02.13 | 12:05 pm
- AstraZeneca Stock Hits New 52-Week High (AZN) 04.29.13 | 01:04 pm
- 4 Stocks Improving Performance Of The Health Care Sector 04.26.13 | 01:04 pm
- AstraZeneca PLC (AZN): Today's Featured Drugs Winner 04.23.13 | 05:04 pm
- AstraZeneca Reaches New 52-Week High (AZN) 04.22.13 | 12:04 pm
- 4 Buy-Rated Dividend Stocks 04.19.13 | 11:04 am
- AstraZeneca Stock Hits New 52-Week High (AZN) 04.09.13 | 11:04 am
- Astra, Rigel Arthritis Pill Posts Mixed Trial Results 04.05.13 | 05:04 am
- Cramer's 6 Stocks in 60 Seconds: YELP NAT AZN HBI TXN URBN (Update 1) 04.02.13 | 05:04 pm
Press Releases for AZN
- AstraZeneca To Establish Strategic R&D Center In Gaithersburg, Md; Wilmington Remains North America Commercial Headquarters - Business Wire 03.18.13 | 09:03 am
- AstraZeneca Encourages Atherosclerosis Education Among High Risk Patients During American Heart Month - PR Newswire 02.14.13 | 09:02 am
- AstraZeneca Recognized As A Top Company For Female Executives - Business Wire 02.05.13 | 12:02 pm
- AstraZeneca HealthCare Foundation: Connections For Cardiovascular HealthSM Accepting Grant Applications - Business Wire 01.09.13 | 09:01 am
- BRILINTA (Ticagrelor) Receives Additional Class I Recommendation In Updated ACCF/AHA Guidelines For The Management Of STEMI Patients - Business Wire 12.17.12 | 03:12 pm
- CRESTOR® US Patent Upheld By Court Of Appeals For The Federal Circuit - Business Wire 12.14.12 | 01:12 pm
- AstraZeneca Updates US Label For FASLODEX® (fulvestrant) Injection - Business Wire 12.05.12 | 11:12 am
- Kaplan-Meier Estimates (Graphic: AstraZeneca) - Business Wire 12.05.12 | 08:12 am
- AstraZeneca To Present Key New Data For Hormone Receptor-Positive Metastatic Breast Cancer At The 35th CTRC-AACR Annual San Antonio Breast Cancer Symposium - Business Wire 12.04.12 | 02:12 pm
- AstraZeneca Makes Major Commitment To Help Patients With Acute Coronary Syndrome Have BRILINTA (ticagrelor) Available In Their Local Communities - Business Wire 12.04.12 | 09:12 am
Partner Headlines for AZN
- Biotech Alkermes Poised To Swell On Pipeline Wins - Investor's Business Daily 04.16.13 | 05:04 pm
- European Stocks Weaken on Downbeat U.S. Jobs Data, North Korean Worries - NASDAQ 04.05.13 | 04:04 pm
- Will AstraZeneca’s Patent Setback Put Off These Top Institutional Shareholders? - Wall St. Cheat Sheet 04.02.13 | 12:04 pm
- Analysts: SanDisk Will Beat Estimates and 4 New Opinions Investors Must Take Note Of - Wall St. Cheat Sheet 04.02.13 | 11:04 am
- 10 Sharp Healthcare Dogs Diagnose 7.4% To 62.1% Gains In March - Seeking Alpha 04.01.13 | 09:04 am
- Drug Companies Have Rebounded From The Patent Cliff With Acquisitions Now On The Mind - Seeking Alpha 03.25.13 | 09:03 am
- Top 9 March Healthcare Dogs Mark 3.4% To 28.7% Gains - Seeking Alpha 03.23.13 | 04:03 am
- Astrazeneca PLC (AZN) Ex-Dividend Date Scheduled for February 13, 2013 - NASDAQ 02.11.13 | 02:02 pm
- Equties Will Rise: 6 Solid Stock Alternatives To The SPY - Seeking Alpha 02.09.13 | 03:02 am
- Understanding The Market Opportunity For Pozen's Safer Aspirin - Seeking Alpha 01.16.13 | 09:01 am
